Is Hormone Therapy Right For You?

Hormone replacement therapy (HRT) is a powerful clinical tool — not a cosmetic intervention or a one-size-fits-all solution. Sex hormones influence nearly every system in the body, including the brain, cardiovascular system, musculoskeletal system, immune function, and metabolism. Because of this, prescribing hormone therapy requires careful evaluation, physiologic understanding, and ongoing monitoring.

Our decision to recommend hormone therapy is based on a structured, evidence-based framework designed to maximize benefit while minimizing risk. Below, we outline how that process works.

1. Clinical symptoms are the foundation of decision-making

Hormone therapy is initiated based on clinical indication, not laboratory values alone. Numerous professional societies emphasize that symptoms — particularly those associated with perimenopause and menopause — are central to diagnosis and treatment decisions.

We begin with a comprehensive symptom assessment, including:

• Vasomotor symptoms (hot flashes, night sweats)

• Sleep disturbance

• Mood changes, anxiety, or depressive symptoms

• Cognitive changes (brain fog, memory difficulty)

• Sexual dysfunction and low libido

• Fatigue and decreased exercise tolerance

• Changes in body composition or recovery capacity

  
  

These symptoms are evaluated in context, including timing, progression, severity, and impact on quality of life.

Importantly, symptoms often precede measurable hormonal changes, particularly during perimenopause, when ovarian hormone production becomes erratic rather than uniformly low.

2. Laboratory evaluation provides physiologic context — not a diagnosis

Laboratory testing is an important tool, but hormone levels must be interpreted cautiously. Sex hormones fluctuate:

• Diurnally

• Across the menstrual cycle

• In response to stress, illness, and caloric intake

• During the menopausal transition

  
  

For this reason, we do not rely on isolated lab values. Instead, labs are used to:

• Establish baseline physiology

• Identify trends or relative deficiencies

• Assess hormone relationships (e.g., estradiol to progesterone balance)

• Evaluate binding proteins such as sex hormone–binding globulin (SHBG)

• Monitor response and safety once therapy is initiated

  
  

Reference ranges reflect population averages — not necessarily optimal function for an individual patient. Clinical symptoms and physiologic plausibility must align.

3. Understanding hormone physiology and mechanism of action

Sex hormones exert their effects by binding to intracellular and membrane-bound receptors, influencing gene transcription, neurotransmitter signaling, vascular tone, bone remodeling, and metabolic regulation.

For example:

• Estradiol plays a key role in thermoregulation, bone density, lipid metabolism, endothelial function, and cognitive processing.

• Progesterone has neuroactive effects, influences sleep architecture, and modulates estrogen’s effects on target tissues.

• Testosterone contributes to libido, energy, muscle mass, bone density, and mood in women, though at significantly lower physiologic levels than in men.

Hormone therapy aims to support physiologic signaling, not override it. Supraphysiologic dosing increases risk without improving outcomes.

4. Differential diagnosis: ruling out non-hormonal contributors

Many symptoms attributed to “hormone imbalance” can arise from other causes. Before initiating hormone therapy, we evaluate for alternative or contributing conditions, including:

• Thyroid dysfunction

• Iron deficiency or anemia

• Vitamin B12 or vitamin D deficiency

• Sleep disorders

• Insulin resistance or metabolic dysfunction

• Chronic stress and hypothalamic-pituitary-adrenal (HPA) axis dysregulation

• Medication side effects

Hormone therapy is most effective when these contributors are identified and addressed concurrently. Treating hormones without addressing underlying physiology often leads to suboptimal results.

5. Risk stratification and safety assessment

Hormone therapy is not appropriate for every patient. A thorough risk assessment is essential and includes:

• Personal and family history of hormone-sensitive cancers

• Cardiovascular disease risk factors

• History of thromboembolic events

• Breast health history and screening status

• Metabolic risk profile

• Current medications and potential interactions

Age, time since menopause, and route of administration all influence risk. Current evidence supports that appropriately selected patients, particularly those within 10 years of menopause onset, experience favorable benefit-risk ratios when therapy is initiated thoughtfully.

6. Selecting the appropriate hormone and delivery method

Different hormones — and different delivery methods — have distinct pharmacokinetic and physiologic effects.

Selection is based on:

• The specific deficiency or imbalance identified

• Symptom profile

• Metabolic considerations

• Patient preferences and lifestyle

• Ability to monitor and adjust therapy safely

Delivery methods vary in absorption, metabolism, and consistency of serum levels. The goal is predictable, stable hormone exposure that mimics physiologic signaling as closely as possible.

7. Monitoring, reassessment, and longitudinal care

Hormone therapy is not static. After initiation, we monitor:

• Symptom response

• Laboratory trends

• Adverse effects

• Cardiometabolic markers when indicated

• Overall functional outcomes

Adjustments are made incrementally and based on both objective and subjective data. Ongoing reassessment ensures that therapy continues to provide benefit without introducing unnecessary risk.

When hormone therapy may not be recommended

Hormone therapy may not be appropriate when:

• Symptoms are better explained by non-hormonal causes

• Risks outweigh potential benefits

• A patient prefers non-hormonal strategies

• Further evaluation or stabilization is needed first

In these cases, we focus on evidence-based alternatives and supportive care.

Our clinical philosophy

Hormone therapy is a medical intervention that requires:

• Clear clinical indication

• Informed consent

• Individualized dosing

• Ongoing monitoring

• Willingness to reassess and adjust

  
  

The goal is not optimization for optimization’s sake, but physiologic support that improves quality of life while respecting safety and evidence.

The right decision is not always more intervention — it is the right intervention, at the right time, for the right patient.

References

1. The North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement.

2. American College of Obstetricians and Gynecologists (ACOG). Hormone Therapy and Menopause.

3. Endocrine Society. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.

4. Santoro N, Randolph JF. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011.

5. Manson JE et al. Menopausal hormone therapy and health outcomes. JAMA. 2017.

6. Pinkerton JV, Aguirre FS. Hormone therapy in women. Endocrinol Metab Clin North Am. 2015.

7. Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019.